Featured Story
FDA Articulates High Benefit-Risk Expectations For Drug Developers
The U.S. Food and Drug Administration (FDA) is soliciting comments on significant new draft guidance for companies engaged in drug development. The draft provides recommendations on the use of patient experience data in new drug applications (NDAs) and biologics license applications (BLAs) and sets forth high expectations for generation of evidence on both benefits and risks, including in rare diseases.